Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have completed Study EIG-UBX-001 through Week 24.~* In the opinion of the Principal Investigator, has been generally compliant with study requirements during Study EIG-UBX-001.~* Agrees to use a medically acceptable method of contraception throughout the entire study period.~* Willing and able to comply with scheduled visits, treatment plans, and laboratory tests and other study procedures.~Exclusion Criteria:~* Is pregnant or lactating.~* Concurrent regular use of another leukotriene pathway inhibitor.~* Any reason that, in the opinion of the investigator, precludes the patient from participating in the study.~  1. Any condition that is unstable or that could jeopardize the safety of the patient and his/her compliance in the study~ 2. A serious uncontrolled medical disorder/condition that in the opinion of the investigator would impair the ability of the patient to receive protocol therapy~* An ongoing, drug-related, serious adverse event (SAE).~* Significant/chronic renal insufficiency.~* Transaminases (alanine transaminase, aspartate transaminase) levels \>3 × upper limit of normal (ULN) and/or bilirubin level \>2 × ULN.~* Absolute neutrophil count \<1500 mm3.~* Hemoglobin concentration \<9 g/dL at Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ubenimex (Type: EXPERIMENTAL): ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).